Page last updated: 2024-10-24

B cell negative selection

Definition

Target type: biologicalprocess

Any process leading to negative selection in B cells. Mechanisms of negative selection include anergy and deletion. [GOC:jal]

B cell negative selection is a critical process in the development of a healthy immune system. It eliminates autoreactive B cells, those that recognize and bind to self-antigens, preventing autoimmune diseases. This process occurs in the bone marrow, the primary site of B cell development.

During B cell maturation, immature B cells undergo a series of rearrangements of their immunoglobulin genes, creating a vast repertoire of antigen receptors. These receptors are displayed on the surface of the B cells, allowing them to interact with antigens.

Negative selection occurs when an immature B cell encounters a self-antigen in the bone marrow. This interaction can trigger several outcomes:

1. **Apoptosis (programmed cell death):** If the interaction is strong and persistent, the B cell will undergo apoptosis and be eliminated.

2. **Receptor editing:** In some cases, the B cell can attempt to "edit" its receptor by rearranging its immunoglobulin genes again. This may result in a new receptor that no longer recognizes the self-antigen.

3. **Anergy:** If receptor editing fails or is not possible, the B cell may become anergic. Anergy is a state of unresponsiveness, where the B cell can no longer be activated by its specific antigen.

These mechanisms ensure that only B cells with receptors that recognize foreign antigens are allowed to mature and enter the circulation. This rigorous selection process is essential for maintaining self-tolerance and preventing autoimmune diseases.

The removal of autoreactive B cells is a dynamic process that relies on the presentation of self-antigens by specialized cells in the bone marrow. These cells include stromal cells, macrophages, and dendritic cells. They express a diverse range of self-antigens that B cells are exposed to during their development.

Negative selection is a complex and tightly regulated process. It involves a variety of signaling pathways and molecules that control the fate of B cells. Defects in these pathways can lead to autoimmune diseases.

The successful elimination of autoreactive B cells through negative selection is a fundamental aspect of a healthy immune system. This process plays a vital role in preventing the development of autoimmune diseases by ensuring that the immune system does not attack the body's own tissues.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Bcl-2 homologous antagonist/killerA Bcl-2 homologous antagonist/killer that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q16611]Homo sapiens (human)
Apoptosis regulator BAX An apoptosis regulator BAX that is encoded in the genome of human. [PRO:SY, UniProtKB:Q07812]Homo sapiens (human)

Compounds (7)

CompoundDefinitionClassesRoles
vorinostatvorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
dicarboxylic acid diamide;
hydroxamic acid
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
alexidine dihydrchloride
6-n-tridecylsalicylic acid6-n-tridecylsalicylic acid: structure given in first sourcehydroxybenzoic acid
5,6-dehydrokawain5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source2-pyranones;
aromatic ether
abt-737aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound
anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
meiogynin ameiogynin A: from the bark of Meiogyne cylindrocarpa; structure in first source
jy-1-106JY-1-106: a BH3 alpha-helix mimetic that functions as a pan-Bcl-2 inhibitor; structure in first source